Orexo AB (LTS:0H19) Total Receivables: kr103.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0H19 Orexo AB LTS:0H19
48 GF Score
Price kr24.68
GF Value kr6.30
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orexo AB Total Receivables?

Orexo AB LTS:0H19 48 Total Receivables is kr103.0 Mil as of Jun. 2026. GuruFocus rates LTS:0H19 with a GF Score™ of 48/100 and a GF Value™ of kr6.30 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Orexo AB's Total Receivables for the quarter that ended in Jun. 2026 was kr103.0 Mil.

Orexo AB Total Receivables Historical Data

* Premium members only.

The historical data trend for Orexo AB's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB Total Receivables Chart

Orexo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 227.30 265.20 218.10 240.80 228.30

Orexo AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 208.50 215.40 228.30 90.20 103.00
LTS:0H19
48GF Score
Orexo AB LTS:0H19
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orexo AB Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of kr103.0 Mil mean?
Orexo AB (LTS:0H19) has a Total Receivables of kr103.0 Mil as of Jun. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Orexo AB and its competitors.
Is Orexo AB's Total Receivables too high?
Orexo AB's current Total Receivables is kr103.0 Mil. Overall, Orexo AB has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Total Receivables compare to ZTS and UTHR?
Orexo AB's Total Receivables of kr103.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Orexo AB and its competitors. Orexo AB's current Total Receivables is kr103.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (LTS:0H19) is currently considered Significantly Overvalued. The stock's GF Value™ is kr6.30, compared to a current price of kr24.68 — trading 291.7% above its estimated fair value. The current Total Receivables is kr103.0 Mil. Orexo AB's overall GF Score™ is 48/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Orexo AB (LTS:0H19), the current Total Receivables is kr103.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orexo AB (LTS:0H19) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of kr24.68 is trading 291.7% above its estimated GF Value™ of kr6.30. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for LTS:0H19:

  • Total Receivables: kr103.0 Mil
  • GF Value™: kr6.30 vs. price of kr24.68 (291.7% above fair value)
  • GF Score™: 48/100 with 8 warning signs

No single metric tells the full story. See the LTS:0H19 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
48GF Score

Get the complete analysis for LTS:0H19

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr24.68
Price
kr6.30
GF Value